 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 5 | 1/1 | 返回列表 |
| 查看: 3986 | 回復(fù): 16 | ||||
| 當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖 | ||||
wachina至尊木蟲 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失敗，恒瑞呋格列泛齒亡唇寒 已有16人參與
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作為慢性疾�。禾悄虿〉闹委煟味拘蕴旅�，難怪武田揮淚斬馬謖。值得一提的是，恒瑞也向CFDA申報(bào)了GPR-40激動(dòng)劑呋格列泛，現(xiàn)在心里估計(jì)也是拔涼拔涼的 |
回復(fù)此樓» 收錄本帖的淘帖專輯推薦
 新藥仿藥 |
» 猜你喜歡
見刊快的中文核心期刊
已經(jīng)有2人回復(fù)
-
一志愿天中醫(yī)中藥學(xué)專碩，希望有b區(qū)的老師可以考慮一下我
已經(jīng)有1人回復(fù)
-
藥物學(xué)論文潤(rùn)色/翻譯怎么收費(fèi)?
已經(jīng)有129人回復(fù)
-
調(diào)劑
已經(jīng)有3人回復(fù)
-
藥學(xué)學(xué)碩326求調(diào)劑
已經(jīng)有0人回復(fù)
-
26年博士申請(qǐng)
已經(jīng)有20人回復(fù)
-
求助 苯磷硫胺JP
已經(jīng)有0人回復(fù)
-
100金幣 阿莫西林克拉維酸鉀片BP藥典中提到的克拉維酸聚合物具體結(jié)構(gòu)式是啥？
已經(jīng)有2人回復(fù)
-
膳食補(bǔ)充劑合規(guī)性交流
已經(jīng)有0人回復(fù)
-
一志愿浙大藥學(xué)求調(diào)劑
已經(jīng)有0人回復(fù)
-
高溫高壓反應(yīng)求助
已經(jīng)有3人回復(fù)
天使009
新蟲 (小有名氣)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 317.4
- 帖子: 129
- 在線: 57.4小時(shí)
- 蟲號(hào): 1449481
- 注冊(cè): 2011-10-18
- 專業(yè): 金融學(xué)
8樓2013-12-31 09:35:56
jinshanshi88
木蟲 (著名寫手)
- 應(yīng)助: 5 (幼兒園)
- 金幣: 2359.2
- 帖子: 1236
- 在線: 259.3小時(shí)
- 蟲號(hào): 453008
- 注冊(cè): 2007-11-06
2樓2013-12-30 12:41:43
guri
鐵蟲 (初入文壇)
- 應(yīng)助: 0 (幼兒園)
- 金幣: 74
- 帖子: 6
- 在線: 9.6小時(shí)
- 蟲號(hào): 2285814
- 注冊(cè): 2013-02-18
- 性別: GG
- 專業(yè): 藥物設(shè)計(jì)與藥物信息
3樓2013-12-30 13:06:43
wph75623
銅蟲 (小有名氣)
- 應(yīng)助: 1 (幼兒園)
- 金幣: 159.9
- 帖子: 137
- 在線: 54.9小時(shí)
- 蟲號(hào): 1922830
- 注冊(cè): 2012-08-03
- 專業(yè): 合成藥物化學(xué)
4樓2013-12-30 16:49:55
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 285求調(diào)劑 +4 | AZMK 2026-03-27 | 6/300 |
|
|---|---|---|---|---|
|
|
[考研] 291求調(diào)劑 +12 | hhhhxn.. 2026-03-23 | 18/900 |
|
|
[考研] 0703化學(xué) +6 | 妮妮ninicgb 2026-03-27 | 6/300 |
|
|
|
[考研] 一志愿華東理工大學(xué)081700，初試分?jǐn)?shù)271 +6 | kotoko_ik 2026-03-23 | 7/350 |
|
|
|
[考研] 315調(diào)劑 +4 | 0860求調(diào)劑 2026-03-26 | 5/250 |
|
|
|
[考研] 材料求調(diào)劑 +5 | .m.. 2026-03-25 | 5/250 |
|
|
|
[考研] 0703化學(xué)一志愿南京師范大學(xué)303求調(diào)劑 +3 | zzffylgg 2026-03-24 | 3/150 |
|
|
|
[考研] 336材料求調(diào)劑 +7 | 陳瀅瑩 2026-03-26 | 9/450 |
|
|
|
[考研] 329求調(diào)劑 +5 | 1() 2026-03-22 | 5/250 |
|
|
|
[考研] 生物學(xué) 296 求調(diào)劑 +4 | 朵朵- 2026-03-26 | 6/300 |
|
|
|
[考研] 279求調(diào)劑 +6 | 紅衣隱官 2026-03-21 | 6/300 |
|
|
|
[考研] 309求調(diào)劑 +4 | gajsj 2026-03-25 | 5/250 |
|
|
|
[考研] 299求調(diào)劑 +4 | 15188958825 2026-03-25 | 4/200 |
|
|
|
[考研] 303求調(diào)劑 +6 | 藍(lán)山月 2026-03-25 | 6/300 |
|
|
|
[考研] 0854AI CV方向招收調(diào)劑 +4 | 章小魚567 2026-03-23 | 4/200 |
|
|
|
[考研] 300求調(diào)劑，材料科學(xué)英一數(shù)二 +5 | leaflight 2026-03-24 | 5/250 |
|
|
|
[考研] 求調(diào)劑 +7 | 十三加油 2026-03-21 | 7/350 |
|
|
|
[考研] 一志愿重慶大學(xué)085700資源與環(huán)境，總分308求調(diào)劑 +7 | 墨墨漠 2026-03-23 | 8/400 |
|
|
|
[考研] 接收2026碩士調(diào)劑(學(xué)碩+專碩) +4 | allen-yin 2026-03-23 | 6/300 |
|
|
|
[考研] 求調(diào)劑 +3 | .m.. 2026-03-21 | 4/200 |
|